SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Novo Nordisk Reports About 21% Weight Loss With Lower-Dose CagriSema

Novo Nordisk said its investigational obesity treatment CagriSema achieved estimated average weight loss of approximately 21% in Phase III REDEFINE 9 trials.

NVO

Related stories